Bethany Sensenig
CIK 1899935 · Chief Financial Officer · last filed 2026-11-04
Bethany Sensenig is a Chief Financial Officer who has filed 19 SEC Form 4 insider transactions across 4 companies since 2022. The most recent filing, for SUPN, was dated Nov 4, 2026. Across all open-market trades the lifetime net is −$466.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $47.9K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SUPN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
8480 HONEYCUTT ROAD, SUITE 120
RALEIGH, NC 27615
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SUPN | Director | 0 | $28.75 | $0 | -$455.1K | 9 | 2026-11-04 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | — | $27.00 | — | $0 | 2 | 2026-06-11 |
| ACOG | Director | 5,489 | $8.73 | $47.9K | $0 | 1 | 2026-04-17 |
| 9 METERS BIOPHARMA, INC. (NMTR) Delisted | Chief Financial Officer | 41,077 | $0.07 | $3.0K | -$11.0K | 3 | 2023-04-21 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-11-04 | SUPN | Other (J) | — | $0 | EDGAR |
| 2026-11-04 | SUPN | Other (J) | — | $0 | EDGAR |
| 2026-06-11 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-04-17 | ACOG | Grant (A) | +5,489 | $0 | EDGAR |
| 2026-02-23 | SUPN | Mixed | — | -$228.3K | EDGAR |
| 2026-02-20 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2026-02-19 | — | Notice (144) | −4,475 | -$224.6K | EDGAR |
| 2025-10-02 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-08-18 | SUPN | Sell (S) | −5,369 | -$226.8K | EDGAR |
| 2025-08-14 | — | Notice (144) | −5,369 | -$228.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.